Canada Prothrombin Complex Concentrate (PCC) Market Size, Share & Industry Analysis, By Product (Beriplex, Octaplex, and Others), By Use Case (Rapid Reversal of Oral Vitamin K Antagonists in Patients with Major Bleeding, Rapid Reversal of VKAs in Patients with a Moderate to High Risk of Bleeding, and Others), By End User (Hospitals & ASCs, Specialty Clinics, and Others), and Regional Forecast, 2025-2032

The Canada prothrombin complex concentrate (PCC) market size was valued at USD 18.5 million in 2024. The market is projected to grow from USD 20.3 million in 2025 to USD 41.1 million by 2032, exhibiting a CAGR of 10.61% during the forecast period.

PCCs are plasma-derived concentrates containing coagulation factors used primarily for the rapid reversal of vitamin K antagonists (e.g., warfarin), management of major bleeding disorders, and targeted factor replacement in surgical and emergency settings. The Canada PCC market is anticipated to witness significant growth throughout the forecast period. This can be attributed to the increasing usage in surgical interventions, supportive regulatory & reimbursement scenarios, and other factors.

Furthermore, many key industry players, including Octapharma AG, CSL, and others are focusing on strategic initiatives to maintain their market positions in the Canadian market.

MARKET DYNAMICS

MARKET DRIVERS

Growing Adoption in Cardiac and Trauma Surgery to Drive the Market Growth

One of the key factors driving the Canada prothrombin complex concentrate (PCC) market growth is the rising adoption of PCC in cardiac and trauma surgeries. Advantages offered by PCC therapies such as better hemostatic effectiveness and fewer serious adverse events have supported their increasing adoption across surgeries. This is supplemented by an increasing number of cardiac and trauma surgeries in the country. All these factors collectively drive the global market growth.

• For instance, according to the Montreal General Hospital, 1200-1500 trauma acute cases are operated per year.

MARKET RESTRAINTS

Variation in Clinical Practice to Limit the Market Growth

Differences in provincial protocols and clinician comfort contribute to uneven adoption across Canada, in turn limiting the market growth. Some centers follow guideline-driven protocols that prioritize PCC for VKA and selected DOAC bleeds, while others still rely heavily on plasma or reserve PCC for only the sickest patients, which hampers the market growth. Variations in dosing strategies also vary, creating uncertainty about optimal regimens and resulting in delayed product adoption.

MARKET OPPORTUNITIES

Adoption in Liver Disease, Trauma, and Critical-Care Algorithms Offers Significant Growth Opportunities

The adoption of PCC into liver disease, trauma, and critical-care algorithms is a major growth opportunity as it moves use beyond classic VKA reversal into broader coagulopathy management. Emerging evidence and reviews in trauma-induced coagulopathy and liver disease describe PCC as part of multimodal resuscitation, supporting its use even in patients not on VKAs.

• For instance, Trauma Services BC guideline for trauma-based massive hemorrhage explicitly includes clotting factor concentrates such as PCC in its massive hemorrhage and anticoagulation-reversal algorithm.

CANADA PROTHROMBIN COMPLEX CONCENTRATE (PCC) MARKET TRENDS

Guideline-driven Substitution of Fresh Frozen Plasma (FFP) with PCC is a Significant Trend

A key emerging trend in the Canada prothrombin complex concentrate market is the guideline-driven substitution of fresh frozen plasma (FFP) with PCC. Emergency and perioperative protocols increasingly recommend PCC for rapid factor replenishment and anticoagulant reversal, reducing the reliance on FFP and shortening the time-to-correction in critical bleeds.

MARKET CHALLENGES

Cost and Budgetary Impact Pose as Significant Challenges for the Market

Cost and budgetary impact pose as significant challenges for the growth of the market. The currently available products are high-cost, plasma-derived biologics resulting in financial burden on patients. Additionally, the poor reimbursement scenario in some regions also hampers the market growth to certain extent.

• For instance, according to a study published by AHAIASA Journals, in March 2021, the cost of the standard dose of PCC was CAD 36,000 (USD 26,277).

Download Free sample to learn more about this report.

Segmentation Analysis

By Product

Wide Product Penetration to Propel Octaplex Segment Growth

Based on product, the market is divided into Beriplex, Octaplex, and others.

To know how our report can help streamline your business, Speak to Analyst

The Octaplex segment is expected to dominate the market with the largest share during the forecast period. The dominance of the segment is attributed to the high penetration of the product in the market, strong clinical comfort & safety data, and supportive clinical guidelines for the use of the product.

• For instance, according to Provincial Blood Coordinating Program data published in May 2025, Octaplex is recommended for use in Canada.

Moreover, the Beriplex segment is expected to grow at a CAGR of 13.39% during the forecast period.

By Use Case

High Number of Patient Visits to Drive the Segmental Growth of Hospitals & ASCs

Based on use case, the market is divided into rapid reversal of oral vitamin K antagonists in patients with major bleeding, rapid reversal of VKAs in patients with a moderate to high risk of bleeding, and others.

In 2024, on the basis of use case, the rapid reversal of oral vitamin K antagonists in patients with major bleeding segment captured the largest Canada prothrombin complex concentrate (PCC) market share. Furthermore, the segment is set to hold a 62.7% share in 2025. This is majorly driven by the high adoption of PCC for life-threatening warfarin-associated bleeding.

• For instance, the National Advisory Committee on Blood and Blood Products in Canada has recommended the use of PCC for this application.

In addition, the others segment is projected to grow at a CAGR of 16.71% during the study period.

By End User

Need for Acute Care Hospitals to Manage Life-threatening Conditions to Drive theHospitals & ASCs Segmental Growth

Based on end user, the market is segmented into specialty clinics, hospitals & ASCs, and others.

In 2024, the hospitals & ASCs segment dominated the Canada prothrombin complex concentrate market with the largest share. Furthermore, the segment is set to hold an 86.0% share in 2025. The dominance can be attributed to the need for acute-care hospitals or large ASCs to manage life-threatening bleeding, stroke, trauma and urgent surgery where PCC is required. Additionally, patient support programs offered by several hospitals in Canada further support the segmental dominance.

In addition, the specialty clinics segment is projected to grow at a CAGR of 14.34% during the study period.

COMPETITIVE LANDSCAPE

Key Industry Players

Strategic Collaborations with Regulatory Bodies to Strengthen their Market Positions

The Canada prothrombin complex concentrate market reflects a highly consolidated structure, with prominent players such as CSL Behring LLC., and Octapharma AG anticipated to hold the maximum market share in 2025. Prominent factors such as agreements with Canadian Blood Services (CBS) and Héma-Québec has resulted in a leading position of these companies in the market.

Another notable player in the market is Takeda Pharmaceutical Company Limited. The company has anti-inhibitor coagulant complex approved for use in hemophilia A and B patients.

LIST OF KEY PROTHROMBIN COMPLEX CONCENTRATE COMPANIES PROFILED:

• CSL Behring LLC. (U.S.)
• Octapharma AG (Switzerland)

KEY INDUSTRY DEVELOPMENTS

• March 2025: Octapharma Canada announced that JAMA Journal published FARES-II trial study that demonstrated that Octaplex significantly reduces the need for additional blood transfusions, improves hemostatic efficacy, and offers safety advantages over FP.
• August 2024: A Canadian study published in The Journal of Thrombosis and Haemostasis (JTH) demonstrated the use of Octaplex during emergency surgery to manage bleeding risk in patients on FXa Inhibitors.

REPORT COVERAGE

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation